Reata Pharmaceuticals

Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. The company was founded by W. Christian Wigley, Waldemar Priebe, Philip J. Thomas, Jef Karel de Brabander, Thomas C. Sudhof, Jonathan M. Graff, and J. Warren Huff in 2002 and is headquartered in Irving, TX.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q2 2024

Reata Pharmaceuticals advances SKYCLARYS, faces impurity challenges and growth opportunities

Reata Pharmaceuticals is making significant progress with FDA approvals and commercialization plans for SKYCLARYS. The company is strategically managing resources and focusing on key programs for long-term sustainability. Challenges with impurity issues and discontinuation of bardoxolone program are being addressed while opportunities for label expansion and new asset exploration are being pursued.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Reata Pharmaceuticals is a biopharmaceutical company that develops drugs for cancer, inflammation, and neurodegenerative diseases. It offers antioxidant and inflammation-modulating drugs, as well as drugs that correct protein misfolding. The company also develops drugs for the treatment of renal, cardiovascular, and autoimmune diseases. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005.

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Reata Pharmaceuticals, Inc. (“Reata” or the “Company”) (NASDAQ: RETA) securities, and/or sold Reata put options, between November 9, 2020 and December 8, 2021, inclusive (the “Class Period”). Reata investors have until February 18, 2022 to file a lead plaintiff motion. Investors suffering losses on their Reata investments are encouraged to cont

INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Reata Pharmaceuticals, Inc. (RETA) Investors

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), announces that it has filed a class action lawsuit in the United States District Court for the Eastern District of Texas, captioned Doyle v. Reata Pharmaceuticals, Inc., et al., (Case No. 21-cv-987), on behalf of persons and entities that purchased or otherwise acquired Reata Pharmaceuticals, Inc. (“Reata” or the “Company”) (NASDAQ: RETA) securities, and/or sold Reata put options, between November 9, 2020 and December 8, 202

RETA CLASS ACTION NOTICE: Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Reata Pharmaceuticals, Inc.

Aeglea BioTherapeutics

Bolt Biotherapeutics

At least one of the three could be in store for better news in the future.

3 Biotech Stocks That Sank: Are Any a Bad-News Buy?

The shares of Reata Pharmaceuticals Inc (NASDAQ: RETA) have received a $68 price target from Cantor Fitzgerald. These are the details.

Reata Pharmaceuticals Stock (RETA): $68 Price Target From Cantor Fitzgerald

LOS ANGELES--(BUSINESS WIRE)---- $RETA #investors--The Law Offices of Frank R. Cruz Continues Its Investigation of Reata Pharmaceuticals, Inc. (RETA) on Behalf of Investors

The Law Offices of Frank R. Cruz Continues Its Investigation of Reata Pharmaceuticals, Inc. (RETA) on Behalf of Investors

San Francisco, California--(Newsfile Corp. - December 10, 2021) - Hagens Berman urges Reata Pharmaceuticals, Inc. (NASDAQ: RETA) investors with significant losses to submit your losses now.Visit: www.hbsslaw.com/investor-fraud/RETAContact An Attorney Now: RETA@hbsslaw.com844-916-0895Reata Pharmaceuticals, Inc. (RETA) Investigation: The investigation focuses on Reata's and senior management's statements about the company's Phase 3 (CARDINAL) study evaluating bardoxolone methyl in patients with chronic kidney disease caused by Alport syndrome and the related n

RETA INVESTOR ALERT: Hagens Berman, National Trial Attorneys, Encourages Reata Pharmaceuticals, Inc. (RETA) Investors to Contact Firm's Attorneys, Firm Investigating Possible Securities Law Violations

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, continues its investigation on behalf of Reata Pharmaceuticals, Inc. (“Reata” or the “Company”) (NASDAQ: RETA) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your Reata investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit you

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Its Investigation of Reata Pharmaceuticals, Inc. (RETA) on Behalf of Investors

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith continues its investigation on behalf of Reata Pharmaceuticals, Inc. (“Reata” or the “Company”) (NASDAQ: RETA) investors concerning the Company's possible violations of federal securities laws. On November 9, 2020, Reata announced that its Phase 3 CARDINAL study of bardoxolone in patients with chronic kidney disease by Alport syndrome “met its primary and key secondary endpoints at the end of Year 2.” Due to these results and “a rec

INVESTOR ALERT: Law Offices of Howard G. Smith Continues Its Investigation of Reata Pharmaceuticals, Inc. (RETA) on Behalf of Investors

An FDA advisory committee believes Reata's (RETA) bardoxolone study data does not support the effectiveness of the candidate in slowing the progression of CKD in patients with Alport syndrome.

Reata (RETA) Falls on Negative Advisory Committee Outcome

The biopharmaceutical company got some potentially devastating news from regulators.

Why Reata Pharmaceuticals Stock Got Absolutely Crushed on Thursday

SAN DIEGO, Dec. 9, 2021 /PRNewswire/ -- Shareholder Rights Law Firm Johnson Fistel, LLP, is investigating potential claims against Reata Pharmaceuticals, Inc. (NASDAQ: RETA) ("Reata" or the "Company") for violations of federal securities laws. Reata has claimed in the past that bardoxolone met its primary and secondary endpoints, increased the potential of this therapeutic agent gaining regulatory approval as the first approved therapy for Alport syndrome, and supported the submission of the NDA to the FDA.

(RETA) Alert: Did You Lose Money on Your Reata Pharmaceuticals Investment? Contact Johnson Fistel Regarding Investigation

Aurinia Pharmaceuticals

The market is getting close to new highs again, but choppy performance is likely.

The 2 Nasdaq Biotech Stocks to Watch Thursday

The FDA's Cardiovascular and Renal Drugs Advisory Committee voted that the agency should not approve Reata Pharmaceuticals Inc's (NASDAQ: RETA) bardoxolone methyl capsules to slow the progression of chronic kidney disease in those with the rare Alport syndrome. Adcomm members largely agreed with the agency, citing safety concerns.

Why Are Reata Pharmaceuticals Shares Plunging Premarket?

PLANO, Texas--(BUSINESS WIRE)--Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), today announced the outcome of the U.S. Food and Drug Administration (“FDA”) Cardiovascular and Renal Drugs Advisory Committee (“Committee”) meeting on bardoxolone methyl (“bardoxolone”) for the treatment of patients with chronic kidney disease (“CKD”) caused by Alport syndrome. The Committee voted no on the question of whether the provided evidence demonstrated that bardoxolone is effec

Reata Pharmaceuticals Announces Outcome of FDA Advisory Committee Meeting of Bardoxolone for the Treatment of Patients with Chronic Kidney Disease Caused by Alport Syndrome

SAN FRANCISCO, Dec. 8, 2021 /PRNewswire/ -- Hagens Berman urges Reata Pharmaceuticals, Inc. (NASDAQ: RETA) investors with significant losses to submit your losses now.  Visit: www.hbsslaw.com/investor-fraud/RETA  Contact An Attorney Now: RETA@hbsslaw.com                                                 844-916-0895 Reata Pharmaceuticals, Inc. (RETA) Investigation: The investigation focuses on Reata's and senior management's statements about the company's Phase 3 (CARDINAL) study evaluating bardoxolone methyl in patients with chronic kidney disease caused by Alport syndrome and the related new drug application ("NDA").

RETA INVESTIGATION: Hagens Berman, National Trial Attorneys, Encourages Reata Pharmaceuticals, Inc. (RETA) Investors to Contact Firm's Attorneys, Firm Investigating Possible Securities Law Violations

PLANO, Texas--(BUSINESS WIRE)--Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, announced today that Nasdaq has halted trading of the Company's common stock. The U.S. Food and Drug Administration's (“FDA”) Cardiovascular and Renal Drugs Advisory Committee (“Advisory Committee”) is meeting to review the Company's New Drug Application (“NDA”) for bardoxolone methyl (“bardoxolone”) for the treatment of patients with chronic k

Reata Pharmaceuticals Stock Trading Halted Today; FDA Advisory Committee to Discuss Bardoxolone for the Treatment of Patients With Chronic Kidney Disease Caused by Alport Syndrome

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Reata Pharmaceuticals, Inc. (“Reata” or the “Company”) (NASDAQ: RETA) investors concerning the Company's possible violations of federal securities laws. On December 6, 2021, the FDA released a briefing document regarding Reata's chronic kidney disease drug candidate, bardoxolone methyl. Therein, the FDA stated that the data submitted by Reata did not “demonstrate that bardoxolone is effective

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Reata Pharmaceuticals, Inc. (RETA) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)---- $RETA #investors--The Law Offices of Frank R. Cruz Announces Investigation of Reata Pharmaceuticals, Inc. (RETA) on Behalf of Investors

The Law Offices of Frank R. Cruz Announces Investigation of Reata Pharmaceuticals, Inc. (RETA) on Behalf of Investors

The FDA raises concerns related to data in Reata's (RETA) NDA seeking approval for bardoxolone for treating Alport syndrome. An advisory committee meeting is scheduled tomorrow.

Reata (RETA) Plunges on FDA Concerns for Kidney Failure Drug

New York, New York--(Newsfile Corp. - December 7, 2021) - Wolf Popper LLP is investigating potential securities fraud claims on behalf of purchasers of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) common stock.Reata is a clinical-stage drug company. Reata's lead program is developing the drug bardoxolone methyl for the treatment of chronic kidney disease caused by Alport syndrome ("AS"). In August 2017, Reata announced it enrolled the first patient in the Phase 3 portion of its...

Wolf Popper LLP Announces Investigation on Behalf of Purchasers of Reata Pharmaceuticals, Inc. (RETA) Common Stock

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Reata Pharmaceuticals, Inc. (“Reata” or the “Company”) (NASDAQ: RETA) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your Reata investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securiti

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Reata Pharmaceuticals, Inc. (RETA) on Behalf of Investors

The FDA has raised concerns about one of the company's key pipeline candidates in advance of a crucial meeting.

Why Reata Pharmaceuticals Nose-Dived on Monday

Atlanta, Georgia--(Newsfile Corp. - December 6, 2021) - Holzer & Holzer, LLC is investigating whether Reata Pharmaceuticals, Inc. ("Reata" or the "Company") (NASDAQ: RETA) complied with federal securities laws. On December 6, 2021, the U.S. Food and Drug Administration ("FDA") released briefing documents ahead of an Advisory Committee meeting regarding CARDINAL, a phase 3 study conducted in support of the New Drug Application for bardoxolone. In the briefing documents, the FDA indicated that the...

SHAREHOLDER ALERT: Investigation of Reata Pharmaceuticals, Inc. Announced by Holzer & Holzer, LLC

Investors need to pay close attention to Reata (RETA) stock based on the movements in the options market lately.

Do Options Traders Know Something About Reata (RETA) Stock We Don't?

PLANO, Texas--(BUSINESS WIRE)--Reata Pharmaceuticals, Inc. (Nasdaq: RETA), (“Reata,” the “Company,” “our,” “us,” or “we”), a clinical-stage biopharmaceutical company, today announced the U.S. Food and Drug Administration (“FDA”) has granted Fast Track Designation for omaveloxolone for the treatment of Friedreich's ataxia. “We are pleased to receive Fast Track Designation as it highlights the potential of omaveloxolone to address a significant unmet medical need for the treatment of patients wit

News for Reata Pharmaceuticals Stock (RETA)